Dr. Mark E. Weinstein, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
5 Franklin Ave Ste 102
Belleville, NJ 07109
Who else practices at this address →
Essex County includes primary care (34% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 60
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
NJ license 25MA08190500 -
Pediatrics Physician
NJ license 25MA08190500
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Atlantic Health PArtners (28 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 60
- Services billed
- 675
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 32 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 22 |
| Test to measure rate of airflow | 25 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluticasone Propionate Other prescribers in Belleville, NJ | 162 |
| Azelastine Hcl Other prescribers in Belleville, NJ | 150 |
| Xolair (omalizumab) | 83 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Belleville, NJ | 79 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Belleville, NJ | 52 |
| Dupixent Pen (dupilumab) Other prescribers in Belleville, NJ | 45 |
| Ipratropium Bromide Other prescribers in Belleville, NJ | 38 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Belleville, NJ | 29 |
| Montelukast Sodium Other prescribers in Belleville, NJ | 27 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in Belleville, NJ | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 108 payments worth $23,285 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $14,276 |
|---|---|
| AbbVie Inc. | $7,421 |
| GlaxoSmithKline, LLC. | $269 |
| Genzyme Corporation | $250 |
| AstraZeneca Pharmaceuticals LP | $237 |
| Novartis Pharmaceuticals Corporation | $146 |
| Amgen Inc. | $91.32 |
| Pharming Healthcare, Inc. | $74.30 |
| Compensation for services other than consulting (speaking, faculty) | $21,143 |
|---|---|
| Food and Beverage | $2,143 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) TAKHZYRO · GENETIC DISEASE | $4,648 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) TAKHZYRO · GENETIC DISEASE | $4,648 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) TAKHZYRO · GENETIC DISEASE | $4,648 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,150 |
| AbbVie Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,350 |
| AbbVie Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,350 |
| AbbVie Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,350 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $101,384 in research payments for these studies, mostly to the institutions running them.
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy.
Novartis Pharmaceuticals Corporation - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.